How soon after injection does semaglutide start working?

What happens in your body in the first 24–72 hours after injecting

Within a day of your first injection, semaglutide is already binding to GLP-1 receptors in the gut, brain and pancreas. GLP-1 receptor agonists work by slowing gastric emptying, increasing the release of insulin in response to food, and signalling fullness to the brain's appetite centres. These mechanisms activate quickly at a biochemical level. If you are wondering how long the semaglutide injection takes to work, the answer starts with plasma concentration, which peaks somewhere between 24 and 72 hours post-injection, according to the NHS semaglutide medicines page, though because the starting dose is intentionally low, the subjective effect may be barely perceptible at first.

That low starting point is the point. The dose titration schedule exists precisely so your digestive system adapts without being overwhelmed. People who expect nausea to signal that the medicine is working often feel nothing and assume something is wrong. In fact, the absence of strong side effects at 0.25 mg is entirely normal and expected. The medicine is still circulating; it simply has not yet reached the concentrations at which appetite suppression becomes noticeable for most users. Patience in the first two weeks is not passive — it is part of the clinical design.

For a fuller picture of semaglutide's pharmacology and what the injection process involves, the semaglutide injection guide covers technique, rotation sites and storage in plain language.

Weeks one to four: when most people first notice a change

A question our prescribers hear most weeks is some version of: "It's been ten days, should I feel something by now?" The honest answer is: maybe, but not necessarily. Appetite changes tend to arrive gradually, and the moment varies between individuals based on body weight, metabolic rate and individual sensitivity to the medicine. What the evidence shows is that by weeks two to four, after a second or third weekly dose, a meaningful proportion of trial participants report reduced hunger and smaller portion sizes feeling satisfying.

By around week four, many people are stepping up from the 0.25 mg starter dose to 0.5 mg, and it is often at this transition that the appetite effect becomes more tangible. The gastric-emptying effect of semaglutide means food stays in the stomach longer, so the feeling of fullness arrives sooner and lasts further into the morning or afternoon. This is not a sudden switch. It builds. Some people describe it as slowly caring less about finishing a meal rather than feeling dramatically full after two bites.

If you are comparing how semaglutide and Wegovy specifically behave in this early period, this page on Wegovy's onset covers the brand-specific detail including the titration steps through to the 2.4 mg maintenance dose.

Months one to six: where the trial data lives

The STEP 1 trial enrolled 1,961 adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. Participants received once-weekly semaglutide 2.4 mg alongside lifestyle support. Average weight loss at 68 weeks was around 15% of body weight, compared with around 2.4% in the placebo group. That headline number does not tell the full story of timing. Weight loss in the trial was not linear: the steepest rate of change occurred roughly between weeks 4 and 20, as doses were being titrated upward and the medicine reached its full therapeutic range.

By 16 weeks, most participants were at or approaching maintenance dose. By 20 weeks, average weight loss in the active group was already around 9–10%. The rate then slowed, with smaller incremental losses through to week 68. This pattern has a practical implication: if very little is happening at month one, it does not predict month three. The medicine's effect compounds with sustained dosing. Stopping early because progress feels slow in week three is the most common reason people miss the window where semaglutide genuinely delivers.

For context on how this compares with Ozempic, which shares the same active ingredient but is licensed for type 2 diabetes rather than weight management, this page on semaglutide and Ozempic explains the distinction clearly.

Factors that affect how quickly you personally respond

Starting body weight, metabolic rate, adherence to the titration schedule, dietary habits alongside treatment, and individual GLP-1 receptor sensitivity all influence how quickly weight loss becomes visible. Clinical trials measure averages across hundreds of participants; any individual's experience sits somewhere in a distribution around that average. Some people see the scales move within the first fortnight. Others reach week six before noticing a change, then see steady progress through months two to four.

Gastrointestinal side effects, principally nausea, constipation and occasional vomiting, are more common in the first few weeks as the body adjusts. These generally ease as dosing stabilises. If side effects feel unmanageable, the clinical team needs to know: dose timing, food choices and hydration all affect tolerability. The Wegovy treatment overview covers the full side-effect profile with practical guidance on managing the adjustment period.

One detail worth knowing: semaglutide accumulates in the body with each weekly injection. Missing a dose interrupts that steady-state build, which is one reason consistency matters more than timing precision within the same day of the week. If you are curious about how long after injection Wegovy works and how that window shifts as doses increase, that page addresses how long a single dose remains active in your system.

Weight-loss medicines work best alongside reduced-calorie eating and regular activity. The weight-loss treatment overview puts semaglutide in context alongside other licensed options and explains how clinical support shapes outcomes over time. Semaglutide (Wegovy) is a prescription-only medicine. A prescriber assesses suitability individually; the results from clinical trials are population averages, not a guarantee of any individual outcome. If you want a clinical review of whether Wegovy is right for you, speaking to our prescribers is the straightforward next step.